Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy Henriette Farkas, MD, PhD, DSc, László Jakab, MD, György Temesszentandrási,

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, to Leanne M. Poulos, BMedSc (Hons), Anne-Marie.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Alveolar nitric oxide and asthma control in mild untreated asthma

Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients Henriette Farkas, MD, PhD, DSc, Dorottya.

Erika Kajdácsi, MSc, Péter K

Allergen immunotherapy: A practice parameter third update

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Fatty acids, inflammation, and asthma

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents James W. Baker, MD, Avner Reshef, MD, Dumitru Moldovan,

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

Activation of the ficolin-lectin pathway during attacks of hereditary angioedema Dorottya Csuka, PhD, Lea Munthe-Fog, PhD, Estrid Hein, MSc, Zsuzsanna.

Fatty acids, inflammation, and asthma

Heleen D. de Koning, MD, Joost Schalkwijk, PhD, Jos W. M

Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients Henriette Farkas, MD, PhD, DSc, Dorottya.

Erika Kajdácsi, MSc, Péter K

Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, to Leanne M. Poulos, BMedSc (Hons), Anne-Marie.

Short-term prophylaxis in a patient with acquired C1-INH deficiency

Hereditary angioedema: Molecular and clinical differences among European populations Matthaios Speletas, MD, PhD, Agnes Szilagyi, PhD, Fotis Psarros,

Rising prevalence of asthma is sex-specific in a US farming population

Hereditary angioedema: Safety of long-term stanozolol therapy

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

The National Biome Initiative: An allergy perspective

A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema

Treatment of chronic autoimmune urticaria with omalizumab

Nonadherence to Asthma Treatment: Getting Unstuck

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Successful treatment of idiopathic angioedema with ecallantide

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug–related urticaria and angioedema Marek L.

Reply Journal of Allergy and Clinical Immunology

Phillip Lieberman, MD, Michael Tankersley, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy Henriette Farkas, MD, PhD, DSc, László Jakab, MD, György Temesszentandrási,

Reply Journal of Allergy and Clinical Immunology

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

High prevalence of severe asthma in a large random population study

A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children Felicia A. Rabito, PhD, MPH, John C. Carlson,

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

One step forward, 2 steps back: The enigma of preschool wheeze

Risk of oral food challenges

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency Marcel Levi, MD,

Reply Journal of Allergy and Clinical Immunology

Measles and immunomodulation

Metallopeptidase activities in hereditary angioedema: Effect of androgen prophylaxis on plasma aminopeptidase P Christian Drouet, PhD, Anik Désormeaux,

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Pru p 3 as a marker for symptom severity for patients with peach allergy in a birch pollen environment Sonja Gaier, MSc, Christina Oberhuber, PhD, Wolfgang.

Environmental factors and eosinophilic esophagitis

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Safety and efficacy of repeated monthly carboplatin desensitization

Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor– associated angioedema Scott A. Hubers, MD, Kevin Kohm, MS, Shouzuo Wei,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy Henriette Farkas, MD, PhD, DSc, László Jakab, MD, György Temesszentandrási, MD, Beáta Visy, MD, György Harmat, MD, PhD, George Füst, MD, PhD, DSc, Gábor Széplaki, MD, Béla Fekete, MD, PhD, DSc, István Karádi, MD, PhD, DSc, Lilian Varga, PhD Journal of Allergy and Clinical Immunology Volume 120, Issue 4, Pages 941-947 (October 2007) DOI: 10.1016/j.jaci.2007.06.026 Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Number of ampoules of hC1-INH concentrate used for the treatment of the patients with HAE during follow-up. A, Number of ampoules received over the lifetime of a patient. B, Average number of ampoules per year (corrected for the duration of follow-up). Journal of Allergy and Clinical Immunology 2007 120, 941-947DOI: (10.1016/j.jaci.2007.06.026) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Time to relief and complete resolution of symptoms after treatment with hC1-INH concentrate. Laryngeal edema responded most rapidly to the treatment and the time for complete resolutions was the shortest compared with gastrointestinal and subcutaneous edema. Both time to relief and complete resolution of symptoms were longest in patients with subcutaneous edema. P values were calculated with the χ2 for trend. Journal of Allergy and Clinical Immunology 2007 120, 941-947DOI: (10.1016/j.jaci.2007.06.026) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Changes of anti–C1-INH autoantibody titers during follow-up. No significant increase or decrease was observed in anti-C1-INH titers during the follow-up of patients with HAE who ever received hC1-INH concentrate. Lines indicate medians and 25th to 75th percentiles. P values were calculated with the Wilcoxon signed-rank test. Journal of Allergy and Clinical Immunology 2007 120, 941-947DOI: (10.1016/j.jaci.2007.06.026) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions